PURE Bioscience to Present at 2017 SeeThru Equity Investor Conference

SAN DIEGO–(BUSINESS WIRE)– PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC)
antimicrobial, today announced that the Company will present at the 2017
SeeThru Equity Investor Conference at 11am EDT on September 27, 2017 at
the Grand Hyatt Hotel, New York.

Hank
R. Lambert, CEO of PURE, will provide business updates on the
commercialization of the Company’s two food safety antimicrobial
products to combat foodborne illness:

• PURE®
  Hard Surface disinfectant:
  • Sales to restaurant chains (including Chipotle Mexican Grill), and
    expanding use with 40+ national food processors/manufacturers
  • Newly developed sanitization solution for food transportation
    vehicles
• PURE
  Control® (FDA/USDA approved direct food contact processing aid):
  • Sales to fresh produce processors; sales and marketing to raw
    poultry parts processors
  • Progress update of USDA in-plant trials for approval for raw
    poultry OLR whole bird processing
  • Est. combined $650M+ US market opportunity for produce and poultry
    processing aids

SDC test results demonstrate materially significant reduction in Salmonella,
Listeria and E. coli contamination in fresh produce; and
dramatic reduction of Salmonella contamination in raw poultry.

The presentation will be webcast live with slides (and available for
replay) and can be accessed at: https://www.purebio.com/investors/events-presentations/.

About SeeThru Equity

Since its founding in 2011, SeeThru Equity has been committed to its
core mission: providing impactful, high quality research on
underfollowed smallcap and microcap equities. SeeThru Equity has
pioneered an innovative business model for equity research that is not
paid for and is unbiased. SeeThru Equity is the host of acclaimed
investor conferences that are the ultimate event for publicly traded
companies with market capitalizations less than $1 billion. SeeThru
Equity is approved to contribute its research reports and estimates to
Thomson One Analytics (First Call), the leading estimates platform on
Wall Street, as well as Capital IQ and FactSet.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety arena —
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and it mitigates bacterial
resistance. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s failure
to implement or otherwise achieve the benefits of its proposed business
initiatives and plans; acceptance of the Company’s current and future
products and services in the marketplace, including the Company’s
ability to convert successful evaluations and tests into customer orders
and customers continuing to place product orders as expected and to
expand their use of the Company’s products; the ability of the Company
to develop effective new products and receive required regulatory
approvals for such products, including the required data and regulatory
approvals required to use its SDC-based technology as a direct food
contact processing aid in raw meat processing and to expand its use in
OLR poultry processing; the Company’s ability to raise funds necessary
to support its continued operations and the implementation of its
business plan; competitive factors; dependence upon third-party vendors,
including to manufacture its products; and other risks detailed in the
Company’s periodic report filings with the Securities and Exchange
Commission (the SEC), including its Form 10-K for the fiscal year ended
July 31, 2016, its Form 10-Q for the first quarter ended October 31,
2016, second quarter ended January 31, 2017, and third quarter ended
April 30, 2017. You should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170914005293/en/